Market Research Report
Global Peptide Therapeutics Market (by Type, Synthesis Technology, Manufacturing Type, Application & Region): Insights & Forecast with Potential Impact of COVID-19 (2022-2026)
|Global Peptide Therapeutics Market (by Type, Synthesis Technology, Manufacturing Type, Application & Region): Insights & Forecast with Potential Impact of COVID-19 (2022-2026)|
Published: June 21, 2022
Content info: 89 Pages
Delivery time: 1-2 business days
The global peptide therapeutics market is expected to record a value of US$44.43 billion in 2026, progressing at a CAGR of 6.95%, over the period 2022-2026. The factors such as surging prevalence of cancer, rising healthcare expenditure, growing incidence of metabolic disorders, increasing geriatric population and accelerating number of approved peptide-based therapeutic drugs. However, the market growth would be challenged by availability of generic or biosimilar peptide therapeutic drugs, high cost of developing drugs and stringent regulatory requirements and production complexity of peptides. The market is anticipated to experience certain trends like expanding volume of peptides driven by generics, rapid adoption of outsourced peptide API and rising investments in research and development of novel drugs.
The global peptide therapeutics market can be segmented on the basis of type, synthesis technology, manufacturing type and application. Based on type, the market can be bifurcated into innovative and generic. According to synthesis technology, the market can be categorized into Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS) and Hybrid Technology. Whereas, on the basis of manufacturing type, the market can be divided outsourced and in-house. In terms of application, the global peptide therapeutics market can be split into chemotherapy, gastroenterology, analgesia, diabetes, pediatric & neonatology and other applications.
The fastest growing regional market is North America due to increasing research and development activities for the development of innovative peptide therapeutics and improvements in healthcare infrastructure coupled with growing prescription of peptide therapeutics on account of high presence of a large number of patients with chronic diseases such as diabetes and cancer.